Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CLN-619 |
Synonyms | |
Therapy Description |
CLN-619 is a humanized monoclonal antibody that targets MICA/MICB, potentially resulting in antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 3506). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CLN-619 | CLN 619|CLN619 | CLN-619 is a humanized monoclonal antibody that targets MICA/MICB, potentially resulting in antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 3506). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05117476 | Phase I | CLN-619 CLN-619 + Pembrolizumab | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | POL | ESP | AUS | 0 |
NCT06381141 | Phase I | CLN-619 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | 0 |